Farmaceutici
Study in rats finds long-term omeprazole use disrupts mineral levels linked to anemia and bone health risks
Riportato dall'IA Immagine generata dall'IA Verificato
Researchers in Brazil report that prolonged use of the proton pump inhibitor (PPI) omeprazole altered iron and calcium measures in adult rats and shifted how several minerals were distributed across organs—changes they say are consistent with higher risks of anemia and possible bone health harms. The authors and Brazil’s health regulator stress that PPIs remain effective for acid-related disorders, but warn against extended, unsupervised use.
Collegium Pharmaceutical, Inc. (COLL) held an investor conference call on March 19, 2026, to discuss its acquisition of AZSTARYS and relevant corporate subsidiaries from Corium Therapeutics. The deal aims to expand the company's position in the ADHD market. Executives including CEO Vikram Karnani joined the call.
Riportato dall'IA
Relmada Therapeutics, Inc. (RLMD) conducted its fourth quarter and full-year 2025 earnings conference call on March 19, 2026, at 4:30 PM EDT. The company released a press release detailing its business update and financial results for the periods ended December 31, 2025. Management highlighted forward-looking statements with associated risks.
Alkermes plc has published a slide deck accompanying its 2025 fourth-quarter earnings call. The materials were made available on February 25, 2026. This release provides insights into the company's financial performance for the period.
Riportato dall'IA
Sarepta Therapeutics, Inc. conducted its fourth quarter 2025 earnings call on February 25, 2026. The company released its financial results earlier that day, with details available on its website. Executives including CEO Douglas Ingram participated in the discussion.
Il ministro egiziano della Salute e della Popolazione Khaled Abdel Ghaffar ha incontrato l'ambasciatore del Kazakistan in Egitto, Askar Zhenis, per discutere il rafforzamento della cooperazione bilaterale in ambito sanitario e tecnologico per la produzione farmaceutica. Abdel Ghaffar ha enfatizzato l'interesse dell'Egitto ad ampliare i legami attraverso il trasferimento di tecnologie per la produzione farmaceutica e l'armonizzazione degli standard di Good Manufacturing Practice. I colloqui hanno riguardato la collaborazione nella produzione farmaceutica, biotecnologia e iniziative di sanità pubblica.
Riportato dall'IA
Chinese biotech firm SciNeuro Pharmaceuticals has partnered with Swiss pharmaceutical giant Novartis in a deal worth nearly $1.7 billion to develop treatments for Alzheimer's disease, which affects some 55 million people worldwide. The agreement grants Novartis exclusive worldwide rights to develop and commercialise SciNeuro's antibody candidates for the progressive brain disease. SciNeuro's novel amyloid beta-targeted antibody programme leverages proprietary blood-brain barrier shuttle technology to help more of the drug cross into the brain where Alzheimer's damage occurs.
L'Egitto intensifica la cooperazione di ricerca con Takeda
10 marzo 2026 18:13Roche shares decline after giredestrant trial fails endpoint
05 marzo 2026 02:11Clara Foods develops world's first animal-free pepsin
02 marzo 2026 08:51Egitto presenta piano integrato per potenziare esportazioni farmaceutiche e abbigliamento
01 marzo 2026 03:28Collegium Pharmaceutical publishes Q4 2025 earnings presentation
17 febbraio 2026 01:32Farmacias Similares avvia espansione in Giappone
14 febbraio 2026 10:20L'Egitto offre competenza certificata dall'OMS per potenziare la produzione di farmaci in Africa
05 febbraio 2026 16:06Japanese drugmakers slump after Trump unveils discount drug website
30 gennaio 2026 21:57Australian sepsis drug advances in human trial
17 gennaio 2026 13:01Delhi high court allows cheaper cancer drug in India